PMID- 10980874
OWN - NLM
STAT- MEDLINE
DCOM- 20001121
LR  - 20191104
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 2
IP  - 1
DP  - 2000 Jan
TI  - Low molecular weight heparins and coronary artery disease.
PG  - 61-8
AB  - Coronary artery disease encompasses a wide spectrum of conditions including 
      silent ischemia, exertional angina, unstable angina, and myocardial infarction. 
      Acute coronary syndromes (unstable angina and myocardial infarction) are caused 
      by the rupture of an atherosclerotic plaque, platelet activation, and fibrin 
      deposition resulting in thrombosis. Aspirin and unfractionated heparin (UFH) have 
      traditionally been the treatment of choice in patients with acute coronary 
      syndromes; however, low molecular weight heparins (LMWHs) offer potential 
      advantages over UFH. Available evidence indicates that LMWH is superior to UFH in 
      reducing ischemic events or death in the acute phase of unstable angina or 
      non-Q-wave myocardial infarction. Long-term therapy with lower doses of LMWH may 
      not offer any advantage to aspirin in the prevention of coronary events or death. 
      Major bleeding complications are similar for LMWH and UFH although minor bleeding 
      complications are more common with LMWH, primarily due to injection-site 
      hematomas. Finally, use of LMWH appears to be cost- effective compared with UFH. 
      The available evidence supports improved clinical outcomes, favorable safety 
      profile, and cost savings associated with LMWH use in the management of unstable 
      angina and non-Q-wave myocardial infarction and should be favored over UFH.
FAU - Zed, P J
AU  - Zed PJ
AD  - CSU Pharmaceutical Sciences, Vancouver Hospital and Health Sciences Center, BC, 
      Canada. zed@interchange.ubc.ca.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Angina, Unstable/drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Enoxaparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
RF  - 44
EDAT- 2000/09/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/12 11:00
PHST- 2000/09/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/12 11:00 [entrez]
AID - 10.1007/s11886-000-0027-0 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2000 Jan;2(1):61-8. doi: 10.1007/s11886-000-0027-0.